Veronica Novotny-Diermayr

Summary

Publications

  1. ncbi SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer
    Veronica Novotny-Diermayr
    S BIO Pte Ltd, 05 09 The Capricorn, Singapore Science Park II, Singapore
    Mol Cancer Ther 9:642-52. 2010
  2. ncbi Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue
    Veronica Novotny-Diermayr
    S BIO Pte Ltd, 1 Science Park Rd, 05 09 The Capricorn, Singapore Science Park II, Singapore 117528
    Mol Cancer Ther 10:1207-17. 2011

Detail Information

Publications2

  1. ncbi SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer
    Veronica Novotny-Diermayr
    S BIO Pte Ltd, 05 09 The Capricorn, Singapore Science Park II, Singapore
    Mol Cancer Ther 9:642-52. 2010
    ..The efficacy of SB939 reported here in two very different models of colorectal cancer warrants further investigation in patients...
  2. ncbi Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue
    Veronica Novotny-Diermayr
    S BIO Pte Ltd, 1 Science Park Rd, 05 09 The Capricorn, Singapore Science Park II, Singapore 117528
    Mol Cancer Ther 10:1207-17. 2011
    ..97, P=0.014). Our data show that the favorable pharmacokinetic and pharmacodynamic properties of SB939 are translated from preclinical models to patients...